EE200300284A - NMDA-retseptori agonisti farmatseutilised kompositsioonid - Google Patents

NMDA-retseptori agonisti farmatseutilised kompositsioonid

Info

Publication number: EE200300284A
Authority: EE; Estonia
Prior art keywords: pharmaceutical compositions; receptor agonist; nmda receptor; nmda; agonist
Prior art date: 2000-12-13

Application number

EEP200300284A

Other languages

English (en)

Estonian (et)

Inventor

Hong Jinyang

Kim Yesook

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2001-12-05

Publication date

2003-10-15

2001-12-05 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-10-15 Publication of EE200300284A publication Critical patent/EE200300284A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EEP200300284A 2000-12-13 2001-12-05 NMDA-retseptori agonisti farmatseutilised kompositsioonid EE200300284A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25537200P	2000-12-13	2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en)	2000-12-13	2001-12-05	Nmda receptor agonist pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
EE200300284A true EE200300284A (et)	2003-10-15

Family

ID=22968017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300284A EE200300284A (et)	2000-12-13	2001-12-05	NMDA-retseptori agonisti farmatseutilised kompositsioonid

Country Status (41)

Country	Link
US (2)	US6635270B2 (xx)
EP (1)	EP1347760B1 (xx)
JP (1)	JP2004515529A (xx)
KR (1)	KR100533407B1 (xx)
CN (1)	CN1273135C (xx)
AP (1)	AP1235A (xx)
AR (1)	AR035607A1 (xx)
AT (1)	ATE296629T1 (xx)
AU (2)	AU1845402A (xx)
BG (1)	BG107788A (xx)
BR (1)	BR0116085A (xx)
CA (1)	CA2431172A1 (xx)
CZ (1)	CZ20031543A3 (xx)
DE (1)	DE60111265T2 (xx)
DO (1)	DOP2001000300A (xx)
DZ (1)	DZ3484A1 (xx)
EA (1)	EA006489B1 (xx)
EC (1)	ECSP034655A (xx)
EE (1)	EE200300284A (xx)
ES (1)	ES2239648T3 (xx)
GE (1)	GEP20053568B (xx)
HR (1)	HRP20030473A2 (xx)
HU (1)	HUP0400645A2 (xx)
IL (1)	IL155810A0 (xx)
IS (1)	IS6811A (xx)
MA (1)	MA26970A1 (xx)
MX (1)	MXPA03005257A (xx)
NO (1)	NO20032678L (xx)
NZ (1)	NZ525742A (xx)
OA (1)	OA12414A (xx)
PA (1)	PA8534901A1 (xx)
PE (1)	PE20020710A1 (xx)
PL (1)	PL362080A1 (xx)
PT (1)	PT1347760E (xx)
SK (1)	SK6982003A3 (xx)
TN (1)	TNSN01173A1 (xx)
UA (1)	UA73619C2 (xx)
UY (1)	UY27068A1 (xx)
WO (1)	WO2002047685A2 (xx)
YU (1)	YU41103A (xx)
ZA (1)	ZA200303892B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2368553T3 (en)	2003-04-08	2015-02-09	Progenics Pharm Inc	Pharmaceutical preparation comprising methylnaltrexone
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
US20080262228A1 (en) *	2006-11-28	2008-10-23	Wyeth	Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof
CL2008000119A1 (es) *	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101317844B (zh) *	2007-06-08	2010-11-17	章劲夫	化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
MX2011003015A (es)	2008-09-18	2011-11-18	Univ Northwestern	Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
ES2706063T3 (es)	2010-02-11	2019-03-27	Univ Northwestern	Agonistas del receptor de NMDA y usos del mismo
CN102586243A (zh) *	2012-03-08	2012-07-18	中国人民解放军军事医学科学院放射与辐射医学研究所	一种预防电磁辐射致脑损伤的标志物
EP2919788A4 (en)	2012-11-14	2016-05-25	Univ Johns Hopkins	METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
AU2014212501A1 (en)	2013-01-29	2015-07-30	Aptinyx, Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
PL2951183T3 (pl)	2013-01-29	2019-08-30	Aptinyx Inc.	Spiro-laktamowe modulatory receptora NMDA i ich zastosowania
WO2014120789A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
EP2951182B1 (en)	2013-01-29	2020-03-18	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (ko)	2013-01-29	2015-10-02	노렉스, 인크.	스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EP3087987A4 (en) *	2013-12-23	2017-08-02	Samyang Biopharmaceuticals Corporation	Pharmaceutical composition containing palonosetron
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
BR112019001923A2 (pt)	2016-08-01	2019-05-14	Aptinyx Inc.	moduladores de nmda de espiro-lactama e métodos de sua utilização
US11028095B2 (en)	2016-08-01	2021-06-08	Aptinyx Inc.	Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
MX383650B (es)	2016-08-01	2025-03-14	Aptinyx Inc	Moduladores del receptor nmda espiro-lactam y uso de los mismos.
PE20190500A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores del receptor nmda spiro-lactam y uso de los mismos
CN109890825B (zh)	2016-08-01	2022-03-11	阿普廷伊克斯股份有限公司	螺-内酰胺nmda受体调节剂及其用途
JP7210599B2 (ja)	2018-01-31	2023-01-23	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en)	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
NZ309134A (en) *	1995-08-11	1999-09-29	Pfizer	(1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1- propranolmethanesulfonate trihydrate
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Ceased
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL155810A0 (en)	2003-12-23
US6635270B2 (en)	2003-10-21
HRP20030473A2 (en)	2005-04-30
NO20032678D0 (no)	2003-06-12
WO2002047685A2 (en)	2002-06-20
CN1479617A (zh)	2004-03-03
SK6982003A3 (en)	2004-08-03
US20020111366A1 (en)	2002-08-15
ZA200303892B (en)	2004-05-20
DOP2001000300A (es)	2002-05-30
ATE296629T1 (de)	2005-06-15
AR035607A1 (es)	2004-06-16
UA73619C2 (en)	2005-08-15
OA12414A (en)	2006-04-18
DZ3484A1 (fr)	2002-06-20
EP1347760B1 (en)	2005-06-01
AU2002218454B2 (en)	2005-10-27
NZ525742A (en)	2005-07-29
UY27068A1 (es)	2002-07-31
CZ20031543A3 (cs)	2004-06-16
JP2004515529A (ja)	2004-05-27
PE20020710A1 (es)	2002-08-09
MXPA03005257A (es)	2003-09-25
TNSN01173A1 (fr)	2005-11-10
ECSP034655A (es)	2003-07-25
NO20032678L (no)	2003-06-12
BR0116085A (pt)	2003-12-23
MA26970A1 (fr)	2004-12-20
HUP0400645A2 (hu)	2004-06-28
IS6811A (is)	2003-05-08
ES2239648T3 (es)	2005-10-01
HK1059575A1 (en)	2004-07-09
AP1235A (en)	2004-01-06
KR20030070060A (ko)	2003-08-27
WO2002047685A3 (en)	2002-08-15
DE60111265D1 (de)	2005-07-07
EA006489B1 (ru)	2005-12-29
BG107788A (bg)	2004-01-30
EP1347760A2 (en)	2003-10-01
CN1273135C (zh)	2006-09-06
US20040039022A1 (en)	2004-02-26
AP2001002376A0 (en)	2001-12-31
PT1347760E (pt)	2005-09-30
CA2431172A1 (en)	2002-06-20
PA8534901A1 (es)	2002-08-26
PL362080A1 (en)	2004-10-18
DE60111265T2 (de)	2006-05-04
YU41103A (sh)	2006-05-25
KR100533407B1 (ko)	2005-12-02
EA200300514A1 (ru)	2003-10-30
AU1845402A (en)	2002-06-24
GEP20053568B (en)	2005-07-11

Publication	Publication Date	Title
EE200300284A (et)	2003-10-15	NMDA-retseptori agonisti farmatseutilised kompositsioonid
FR2795324B1 (fr)	2002-05-17	Compositions pharmaceutiques stabilisees
AR028204A1 (es)	2003-04-30	Composiciones farmaceuticas electrohiladas
IS2991B (is)	2017-12-15	Lyfjafræðileg nanóagna samsetning takykínín viðtakamótlyfs
EE200200437A (et)	2003-12-15	Manipuleerimiskindlad peroraalsed opioidagonisti preparaadid
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
NO20030418D0 (no)	2003-01-27	Nytt farmasöytisk preparat
PL365377A1 (en)	2005-01-10	Amide derivatives as nmda receptor antagonists
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
ATE291900T1 (de)	2005-04-15	5ht1-rezeptoragonist enthaltendes arzneimittel
IS7051A (is)	2003-11-26	Lyfjasamsetningar
NO20026123L (no)	2003-02-18	Farmasöytiske sammensetninger
MA26890A1 (fr)	2004-12-20	Metabolites agonistes/ antagonistes d'oestrogenes
NO20031095L (no)	2003-03-10	Farmasoytiske sammensetninger
DK1347760T3 (da)	2005-09-05	Farmaceutiske kompositioner med NMDA receptor agonister
EE200200689A (et)	2004-06-15	Ravimkoostised
DK1450770T3 (da)	2005-08-01	Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist